» Articles » PMID: 35064957

A Workflow for the Joint Modeling of Longitudinal and Event Data in the Development of Therapeutics: Tools, Statistical Methods, and Diagnostics

Overview
Publisher Wiley
Specialty Pharmacology
Date 2022 Jan 22
PMID 35064957
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical trials investigate treatment endpoints that usually include measurements of pharmacodynamic and efficacy biomarkers in early-phase studies and patient-reported outcomes as well as event risks or rates in late-phase studies. In recent years, a systematic trend in clinical trial data analytics and modeling has been observed, where retrospective data are integrated into a quantitative framework to prospectively support analyses of interim data and design of ongoing and future studies of novel therapeutics. Joint modeling is an advanced statistical methodology that allows for the investigation of clinical trial outcomes by quantifying the association between baseline and/or longitudinal biomarkers and event risk. Using an exemplar data set from non-small cell lung cancer studies, we propose and test a workflow for joint modeling. It allows a modeling scientist to comprehensively explore the data, build survival models, investigate goodness-of-fit, and subsequently perform outcome predictions using interim biomarker data from an ongoing study. The workflow illustrates a full process, from data exploration to predictive simulations, for selected multivariate linear and nonlinear mixed-effects models and software tools in an integrative and exhaustive manner.

Citing Articles

Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia.

Tettamanti F, Kimko H, Sharma S, Di Veroli G Clin Transl Sci. 2024; 17(8):e13905.

PMID: 39164859 PMC: 11335580. DOI: 10.1111/cts.13905.


Joint modeling of monocyte HLA-DR expression trajectories predicts 28-day mortality in severe SARS-CoV-2 patients.

Baudemont G, Tardivon C, Monneret G, Cour M, Rimmele T, Garnier L CPT Pharmacometrics Syst Pharmacol. 2024; 13(7):1130-1143.

PMID: 38837680 PMC: 11247117. DOI: 10.1002/psp4.13145.


Model-based prediction of progression-free survival for combination therapies in oncology.

Baaz M, Cardilin T, Jirstrand M CPT Pharmacometrics Syst Pharmacol. 2023; 12(9):1227-1237.

PMID: 37300376 PMC: 10508530. DOI: 10.1002/psp4.13003.


Joint modeling under competing risks: Application to survival prediction in patients admitted in Intensive Care Unit for sepsis with daily Sequential Organ Failure Assessment score assessments.

Lavalley-Morelle A, Timsit J, Mentre F, Mullaert J CPT Pharmacometrics Syst Pharmacol. 2022; 11(11):1472-1484.

PMID: 36201150 PMC: 9662207. DOI: 10.1002/psp4.12856.


Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma.

Yao Y, Wang Z, Yong L, Yao Q, Tian X, Wang T CPT Pharmacometrics Syst Pharmacol. 2022; 11(9):1170-1182.

PMID: 35758865 PMC: 9469699. DOI: 10.1002/psp4.12835.


References
1.
Gerds T, Schumacher M . Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J. 2007; 48(6):1029-40. DOI: 10.1002/bimj.200610301. View

2.
Singh R, Mukhopadhyay K . Survival analysis in clinical trials: Basics and must know areas. Perspect Clin Res. 2011; 2(4):145-8. PMC: 3227332. DOI: 10.4103/2229-3485.86872. View

3.
Duffull S, Wright D, Winter H . Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol. 2011; 71(6):807-14. PMC: 3099367. DOI: 10.1111/j.1365-2125.2010.03891.x. View

4.
Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos J, Hlatky L . Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol. 2014; 10(8):e1003800. PMC: 4148196. DOI: 10.1371/journal.pcbi.1003800. View

5.
Yin A, Moes D, van Hasselt J, Swen J, Guchelaar H . A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2019; 8(10):720-737. PMC: 6813171. DOI: 10.1002/psp4.12450. View